{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-032974","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.038513+00:00","generated_at":"2026-06-04T23:43:39.649463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q4 net loss $29.2M, revenue $14.8M; cash $195.8M plus $325M PIPE","bullets":["Q4 net loss $29.2M ($0.35 loss per share); revenue $14.8M, up 5% YoY.","Full year 2023 net loss $80.7M ($1.01 loss per share); revenue $58.4M, up 13.4%.","Cash $195.8M at year-end; Feb 2024 PIPE added $325M gross proceeds, funding into at least 2028.","Appointed Pravin Dugel as Executive Chairman and three key retinal care leaders.","Phase 3 AXPAXLI SOL-1 screening underway; topline data for diabetic retinopathy and PAXTRAVA glaucoma expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-032974","json":"https://secwatch.observer/filing/0001104659-24-032974.json","markdown":"https://secwatch.observer/filing/0001104659-24-032974.md","text":"https://secwatch.observer/filing/0001104659-24-032974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/tm248311d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:43:39.649463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8ac6d69e30119b20e6a8c5c69142a31dbfb0635","claim":"OCULAR THERAPEUTIX, INC reported the full year ended December 31, 2023 results: revenue $58.4 million.","evidence_excerpt":"Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$58.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fcbed95f8c8200485dfa41bc84a400491bddb666","claim":"OCULAR THERAPEUTIX, INC reported the fourth quarter 2023 results: revenue $14.8 million, net income $(29.2) million, EPS $(0.35) per share on both a basic and diluted basis.","evidence_excerpt":"Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales. Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%. Research and development expenses for the fourth quarter of 2023 were $16.2 million versus $13.5 million for the comparable period in 2022, driven primarily by an increase in overall clinical and regulatory expenses associated with product development programs. Overall R&D expenses for the full year increased $7.6 million to $61.1 million from $53.5 million in 2022, reflecting the timing and conduct of our clinical trials. Selling and marketing expenses were $9.2 million in the fourth quarter of 2023, as compared to $10.5 million for the comparable quarter of 2022, primarily reflecting a reduction in personnel costs driven by lower expense for stock-based compensation and other items. Overall, se","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter 2023"},{"label":"Revenue","value":"$14.8 million"},{"label":"Net income","value":"$(29.2) million"},{"label":"EPS","value":"$(0.35) per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}